Diabetes Mellitus, Type 2 Clinical Trial
— PROMISOfficial title:
Pregnancy Outcomes and Maternal Insulin Sensitivity
NCT number | NCT04315545 |
Other study ID # | 68845 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | February 6, 2020 |
Est. completion date | December 2023 |
The PROMIS study will focus on maternal insulin sensitivity thourghout pregnancy and postpartum in a moderate to high risk population (BMI ≥25 kg/m2) in developing adverse pregnancy outcomes. Next to the OGTT, the meal tolerance test (MTT) will be used as a tool for metabolic testing. The investigators hypothesize that (early) pregnancy assessment of maternal glucose-insulin metabolism with a MTT in a moderate to high risk group identify more mothers at risk for adverse pregnancy outcomes compared with standard OGTT testing at 24-28 weeks.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2023 |
Est. primary completion date | July 2023 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Healthy singleton pregnant women (10-12 weeks of gestation) - BMI =25 kg/m2 - FPG =7.0 mmol/l - Dutch or English speaking - Written informed consent Exclusion Criteria: - Serious health complications (Hypertension, Hyperlipidemia, Asthma, Haemochromatosis) or medication use that influence the glucose metabolism or fetal growth (e.g. corticosteroids). - Multiple pregnancy - pre-existing Diabetes type 1 and 2 defined as FPG =7.0 mmol/l or use of diabetes medication - Participation in any other studies involving the investigation of medication or nutritional products or severe illness or antibiotic use in the two weeks prior to entry into the study - HIV/Hepatitis - Expectation of non-compliance to the study protocol, among others, a fear of needles - Known allergies or intolerances for one or more nutritional ingredients in the MTT - Psychological dysfunctions |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Centre Groningen | Groningen | |
Netherlands | Medical Center Leeuwarden | Leeuwarden |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen |
Netherlands,
Catalano PM, Ehrenberg HM. The short- and long-term implications of maternal obesity on the mother and her offspring. BJOG. 2006 Oct;113(10):1126-33. doi: 10.1111/j.1471-0528.2006.00989.x. Epub 2006 Jul 7. — View Citation
Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol. 1999 Apr;180(4):903-16. doi: 10.1016/s0002-9378(99)70662-9. — View Citation
Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr. 2003 May;133(5 Suppl 2):1674S-1683S. doi: 10.1093/jn/133.5.1674S. — View Citation
Chen C, Xu X, Yan Y. Estimated global overweight and obesity burden in pregnant women based on panel data model. PLoS One. 2018 Aug 9;13(8):e0202183. doi: 10.1371/journal.pone.0202183. eCollection 2018. — View Citation
Cobelli C, Man CD, Sparacino G, Magni L, De Nicolao G, Kovatchev BP. Diabetes: Models, Signals, and Control. IEEE Rev Biomed Eng. 2009 Jan 1;2:54-96. doi: 10.1109/RBME.2009.2036073. — View Citation
Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ. 2008 Jul 29;179(3):229-34. doi: 10.1503/cmaj.080012. Erratum In: CMAJ. 2008 Aug 12;179(4):344. — View Citation
Ferrara A, Peng T, Kim C. Trends in postpartum diabetes screening and subsequent diabetes and impaired fasting glucose among women with histories of gestational diabetes mellitus: A report from the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care. 2009 Feb;32(2):269-74. doi: 10.2337/dc08-1184. Epub 2008 Nov 4. — View Citation
Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements--a prospective study. Am J Obstet Gynecol. 1985 Feb 1;151(3):333-7. doi: 10.1016/0002-9378(85)90298-4. — View Citation
HAPO Study Cooperative Research Group; Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943. — View Citation
Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002 Oct;25(10):1862-8. doi: 10.2337/diacare.25.10.1862. — View Citation
Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, Cockram CS. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem. 1998 Jan;35 ( Pt 1):62-7. doi: 10.1177/000456329803500107. — View Citation
Koning SH, Hoogenberg K, Lutgers HL, van den Berg PP, Wolffenbuttel BH. Gestational Diabetes Mellitus:current knowledge and unmet needs. J Diabetes. 2016 Nov;8(6):770-781. doi: 10.1111/1753-0407.12422. Epub 2016 Jul 28. — View Citation
Koning SH, Hoogenberg K, Scheuneman KA, Baas MG, Korteweg FJ, Sollie KM, Schering BJ, van Loon AJ, Wolffenbuttel BH, van den Berg PP, Lutgers HL. Neonatal and obstetric outcomes in diet- and insulin-treated women with gestational diabetes mellitus: a retrospective study. BMC Endocr Disord. 2016 Sep 29;16(1):52. doi: 10.1186/s12902-016-0136-4. — View Citation
Koning SH, van Zanden JJ, Hoogenberg K, Lutgers HL, Klomp AW, Korteweg FJ, van Loon AJ, Wolffenbuttel BHR, van den Berg PP. New diagnostic criteria for gestational diabetes mellitus and their impact on the number of diagnoses and pregnancy outcomes. Diabetologia. 2018 Apr;61(4):800-809. doi: 10.1007/s00125-017-4506-x. Epub 2017 Nov 22. — View Citation
Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynecol. 2007 Dec;50(4):938-48. doi: 10.1097/GRF.0b013e31815a5494. — View Citation
Langer O, Umans JG, Miodovnik M. The proposed GDM diagnostic criteria: a difference, to be a difference, must make a difference. J Matern Fetal Neonatal Med. 2013 Jan;26(2):111-5. doi: 10.3109/14767058.2012.734874. Epub 2012 Oct 30. — View Citation
Maegawa Y, Sugiyama T, Kusaka H, Mitao M, Toyoda N. Screening tests for gestational diabetes in Japan in the 1st and 2nd trimester of pregnancy. Diabetes Res Clin Pract. 2003 Oct;62(1):47-53. doi: 10.1016/s0168-8227(03)00146-3. — View Citation
Malcolm J, Lawson ML, Gaboury I, Keely E. Risk perception and unrecognized type 2 diabetes in women with previous gestational diabetes mellitus. Obstet Med. 2009 Sep;2(3):107-10. doi: 10.1258/om.2009.080063. Epub 2009 Sep 1. — View Citation
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017 Dec 16;390(10113):2627-2642. doi: 10.1016/S0140-6736(17)32129-3. Epub 2017 Oct 10. — View Citation
Noctor E, Dunne FP. Type 2 diabetes after gestational diabetes: The influence of changing diagnostic criteria. World J Diabetes. 2015 Mar 15;6(2):234-44. doi: 10.4239/wjd.v6.i2.234. — View Citation
Seshiah V, Cynthia A, Balaji V, Balaji MS, Ashalata S, Sheela R, Thamizharasi M, Arthi T. Detection and care of women with gestational diabetes mellitus from early weeks of pregnancy results in birth weight of newborn babies appropriate for gestational age. Diabetes Res Clin Pract. 2008 May;80(2):199-202. doi: 10.1016/j.diabres.2007.12.008. Epub 2008 Feb 4. — View Citation
Sonagra AD, Biradar SM, K D, Murthy D S J. Normal pregnancy- a state of insulin resistance. J Clin Diagn Res. 2014 Nov;8(11):CC01-3. doi: 10.7860/JCDR/2014/10068.5081. Epub 2014 Nov 20. — View Citation
Venkataraman H, Ram U, Craik S, Arungunasekaran A, Seshadri S, Saravanan P. Increased fetal adiposity prior to diagnosis of gestational diabetes in South Asians: more evidence for the 'thin-fat' baby. Diabetologia. 2017 Mar;60(3):399-405. doi: 10.1007/s00125-016-4166-2. Epub 2016 Dec 2. — View Citation
World Health Organization. World health statistics 2016: Monitoring health for the SDGs sustainable development goals. World Health Organization; 2016.
Yang X, Hsu-Hage B, Zhang H, Zhang C, Zhang Y, Zhang C. Women with impaired glucose tolerance during pregnancy have significantly poor pregnancy outcomes. Diabetes Care. 2002 Sep;25(9):1619-24. doi: 10.2337/diacare.25.9.1619. — View Citation
Zhu Y, Zhang C. Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective. Curr Diab Rep. 2016 Jan;16(1):7. doi: 10.1007/s11892-015-0699-x. — View Citation
* Note: There are 26 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | FFQ | Food frequency questionnaire | between week 12-16 of gestation | |
Other | FFQ | Food frequency questionnaire | between 24-28 of gestation | |
Other | FFQ | Food frequency questionnaire | 1 month postpartum | |
Other | FFQ | Food frequency questionnaire | 3 months postpartum | |
Other | AEBQ | Adult eating behaviour questionnaire | between week 12-16 of gestation | |
Other | AEBQ | Adult eating behaviour questionnaire | between 24-28 of gestation | |
Other | AEBQ | Adult eating behaviour questionnaire | 1 month postpartum | |
Other | AEBQ | Adult eating behaviour questionnaire | 3 months postpartum | |
Other | BEBQ | Baby eating behaviour questionnaire | 1 month postpartum in child | |
Other | BEBQ | Baby eating behaviour questionnaire | 3 months postpartum in child | |
Other | EQ | EQ-5D questionnaire | Between week 12-16 of gestation | |
Other | EQ | EQ-5D questionnaire | between week 24-28 of gestation | |
Other | EQ | EQ-5D questionnaire | 1 month postpartum | |
Other | EQ | EQ-5D questionnaire | 3 months postpartum | |
Other | PA | Pregnancy physical activity questionnaire | between week 12-16 of gestation | |
Other | PA | Pregnancy physical activity questionnaire | between week 24-28 of gestation | |
Other | PA | International physical activity questionnaire | 1 month postpartum | |
Other | PA | International physical activity questionnaire | 3 months postpartum | |
Other | MP | Meal test preference questionnaire | In week 24 of gestation | |
Other | MP | Meal test preference questionnaire | In week 25 of gestation | |
Primary | fasting glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=0 min, before intake of test drink | |
Primary | postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=10 min postprandial | |
Primary | postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=20 min postprandial | |
Primary | postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=30 min postprandial | |
Primary | postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=45 min postprandial | |
Primary | postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=60 min postprandial | |
Primary | postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=90 min postprandial | |
Primary | postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | T=120 min postprandial | |
Primary | fasting and postprandial glucose | Bloood will be collected fasted and after intake of the MTT and OGTT | AUC and postprandial curve | |
Primary | fasting insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=0 min, before intake of test drink | |
Primary | postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=10 min postprandial | |
Primary | postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=20 min postprandial | |
Primary | postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=30 min postprandial | |
Primary | postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=45 min postprandial | |
Primary | postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=60 min postprandial | |
Primary | postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=90 min postprandial | |
Primary | postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | T=120 min postprandial | |
Primary | fasting and postprandial insulin | Blood will be collected fasted and after intake of the MTT and OGTT | AUC and postprandial curve | |
Secondary | Triglycerides | Blood will be collected fasted | T=0 min, before intake of test drink | |
Secondary | Total cholesterol | Blood will be collected fasted | T=0 min, before intake of test drink | |
Secondary | HDL-cholesterol | Blood will be collected fasted | T=0 min, before intake of test drink | |
Secondary | Free fatty acids | Blood will be collected fasted | T=0 min, before intake of test drink | |
Secondary | Hba1c | Blood will be collected fasted | T=0 min, before intake of test drink | |
Secondary | Fasting stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=0, before intake of test drink | |
Secondary | postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=10 min postprandial | |
Secondary | postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=20 min postprandial | |
Secondary | postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=30 min postprandial | |
Secondary | postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=45 min postprandial | |
Secondary | postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=60 min postprandial | |
Secondary | postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=90 min postprandial | |
Secondary | postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | T=120 min postprandial | |
Secondary | fasting and postprandial stable glucose isotopes | Blood will be collected fasted and after intake of the MTT and OGTT | AUC and postprandial curve |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |